Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 3,622 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Nivolumab + Plinabulin
Drug
Lead sponsor
Lyudmila Bazhenova, M.D.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
La Jolla, California
Conditions
Lung Cancer
Interventions
ZD1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Docetaxel, Irinotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Solid Tumors
Interventions
RMC-4630
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 9 more
Conditions
Non-small Cell Lung Cancer, Urothelial Cancer
Interventions
Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in combination with gemcitabine / cisplatin., Avelumab 1200 mg in combination with pemetrexed/carboplatin, Avelumab 1200 mg in combination with gemcitabine/cisplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Tucson, Arizona • Stony Brook, New York • The Bronx, New York + 1 more
Conditions
Non Small Cell Lung Cancer
Interventions
Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions
CT scan
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab, Tiragolumab, Matching Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Denver, Colorado • New Haven, Connecticut • St. Petersburg, Florida + 5 more
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Conditions
Lung Neoplasms, Carcinoma, Non-small Cell Lung
Interventions
axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Irvine, California • Orange, California • Chicago, Illinois + 7 more
Conditions
Non Small Cell Lung Cancer
Interventions
ACY-241, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lung Cancer
Interventions
Celecoxib, Docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
CV301, Pembrolizumab, Nivolumab
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more
Conditions
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
Interventions
CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Conditions
Lung Cancer
Interventions
Imetelstat Sodium (GRN163L)
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Dallas, Texas • Houston, Texas + 1 more
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Initiation of pembrolizumab, Initiation of chemotherapy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Conditions
Lung Cancer
Interventions
paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Interventions
Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
165
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Etrumadenant, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Colon, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions
MRTX849, BI 1701963
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
St Louis, Missouri • Cleveland, Ohio • Houston, Texas + 1 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab (Avastin), Carboplatin, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
2
States / cities
Houston, Texas